Virionics Mission |
|
At Virionics, our mission is to develop and commercialize
virus-like particles (VLPs), a groundbreaking, new medical
technology that harnesses the power of the immune system
to treat and prevent a wide variety of diseases. Learn
more >> |
| |
News and Updates |
|
2006.04.04
Virionics Corporation Signs
MediGene AG License Agreement; Acquires Clinical Phase
II CVLP Program Assets in Exchange for Equity
Learn
more >> |
|
 |
What is a Virus-Like Particle (VLP)?
VLPs are genetically-engineered, self-assembled
protein spheres made from recombinant viral proteins. These three
dimensional, multi-antigen particles have already proven to be
safer and more effective as preventative vaccines and immunotherapies
when compared to recombinant protein, DNA, or viral-vectored vaccines.
Learn more >> |
|
VLP Product Development |
|
PapViRx, our lead product, is being prepared to enter an
international Phase II/III clinical trial in 2008.
Learn more >>
HepCVax and HepCiRx for the prevention and treatment of
hepatitis C virus (HCV) is being prepared for pre-clinical
and Phase I clinical trials
Learn more >>
Phase I-II studies of CIgImmune for liver transplant patients
and HepCiRx are planned for 2008.
Virionics plans to collaborate with NGOs to advance novel,
dual-action HIV vaccine for prevention of HIV infection
and AIDS.
Learn more >> |
|
